|
|
|
|
Home | Search | Advance Search | Browse | Online Submission | Documentation & FAQ | Team | Contact us |
|
| PolysacDB ID | 2355 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-1 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 14-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2356 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-2 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 14-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2357 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-4 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 14-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2358 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-5 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 16-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2359 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-6 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 16-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2360 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-7 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 16-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2361 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-8 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 16-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2362 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-10 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 16-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2363 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-11 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 16-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2364 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-12 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 17-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2365 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-13 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 17-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2366 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-14 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 17-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2367 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-17 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 17-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2368 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-18 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 18-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2369 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-20 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 19-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2370 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-21 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 19-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2371 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-22 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 19-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2372 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-23 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 20-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2373 |
| Carbohydrate Name | Type 5 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 17-24 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of four different type 5 S. aureus clinical isolates but with none of the five S. aureus clinical isolates possessing type 8 capsular polysaccharides. This Mab was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 6, and 7, but was reactive with type 4 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 21-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2374 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 18-1 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 21-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2375 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 18-2 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 21-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2376 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 18-4 |
| Antibody type and class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 21-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2377 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 18-5 |
| Antibody type and class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 22-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2378 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 18-8 |
| Antibody type and class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 22-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2379 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 18-9 |
| Antibody type and class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 23-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2380 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 18-10 |
| Antibody type and class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 23-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2381 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 18-11 |
| Antibody type and class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 23-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2382 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed functions | N/A |
| Antigenic Nature used to produce antibodies | Formalinized cells |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab 18-12 |
| Antibody type and class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross-reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed epitopes | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 24-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2383 |
| Carbohydrate Name | Surface Polysaccharide Poly-N-Acetylglucosamine [PNAG] (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | PNAG consists of a backbone of N-acetylglucosamine residues of variable lendth |
| BCSDB Structure | 21574 |
| Proposed functions | PNAG also referred to as the polysaccharide intercellular adhesin, has been shown to elicit opsonic antibodies when used as a vaccine in goats and rabbits. In addition, these polyclonal antibodies passively protect mice against S. aureus bacteremia and renal infection as well as against lethality following a high-dose infection. Animal antibodies to PNAG also mediate killing of S. epidermidis strains that express this antigen, and these strains constitute a significant proportion of clinical isolates |
| Antigenic Nature used to produce antibodies | Staphylococcus aureus infected patients |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab F598 |
| Antibody type and class | IgG1 |
| Assay System | Enzyme-linked immunosorbent assays, complement deposition, immunofluorescence and opsonophagocytic assays |
| Cross-reactivity | This Mab was specfic to S. aureus and was found to be nonreactive against alginate from Pseudomonas aeruginosa strain PAO 581, the P. aeruginosa LPS O antigens from serogroups 02 and 06, and the PS/A antigen of Bacteroides fragilis |
| Proposed epitopes | This Mab bound best to nonacetylated or backbone epitopes on PNAG |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab had superior complement deposition and opsonophagocytic activity. This Mab also had optimal protective efficacy. This Mab could be immunotherapeutic agent for preventing or treating staphylococcal infections. |
| Curator ID | AA + AS |
| Date of Curation | 24-04-2011 |
| References | 16622211 |
| PolysacDB ID | 2384 |
| Carbohydrate Name | Surface Polysaccharide Poly-N-Acetylglucosamine [PNAG] (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | PNAG consists of a backbone of N-acetylglucosamine residues of variable lendth |
| BCSDB Structure | 21574 |
| Proposed functions | PNAG also referred to as the polysaccharide intercellular adhesin, has been shown to elicit opsonic antibodies when used as a vaccine in goats and rabbits. In addition, these polyclonal antibodies passively protect mice against S. aureus bacteremia and renal infection as well as against lethality following a high-dose infection. Animal antibodies to PNAG also mediate killing of S. epidermidis strains that express this antigen, and these strains constitute a significant proportion of clinical isolates |
| Antigenic Nature used to produce antibodies | Staphylococcus aureus infected patients |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab F628 |
| Antibody type and class | IgG1 |
| Assay System | Enzyme-linked immunosorbent assays, complement deposition, immunofluorescence and opsonophagocytic assays |
| Cross-reactivity | This Mab was specfic to S. aureus and was found to be nonreactive against alginate from Pseudomonas aeruginosa strain PAO 581, the P. aeruginosa LPS O antigens from serogroups 02 and 06, and the PS/A antigen of Bacteroides fragilis |
| Proposed epitopes | This Mab bound best to PNAG containing N-acetyl groups |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab had partial complement deposition and opsonophagocytic activity. |
| Curator ID | AA + AS |
| Date of Curation | 24-04-2011 |
| References | 16622211 |
| PolysacDB ID | 2385 |
| Carbohydrate Name | Surface Polysaccharide Poly-N-Acetylglucosamine [PNAG] (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | PNAG consists of a backbone of N-acetylglucosamine residues of variable lendth |
| BCSDB Structure | 21574 |
| Proposed functions | PNAG also referred to as the polysaccharide intercellular adhesin, has been shown to elicit opsonic antibodies when used as a vaccine in goats and rabbits. In addition, these polyclonal antibodies passively protect mice against S. aureus bacteremia and renal infection as well as against lethality following a high-dose infection. Animal antibodies to PNAG also mediate killing of S. epidermidis strains that express this antigen, and these strains constitute a significant proportion of clinical isolates |
| Antigenic Nature used to produce antibodies | Staphylococcus aureus infected patients |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab F630 |
| Antibody type and class | IgG1 |
| Assay System | Enzyme-linked immunosorbent assays, complement deposition, immunofluorescence and opsonophagocytic assays |
| Cross-reactivity | This Mab was specfic to S. aureus and was found to be nonreactive against alginate from Pseudomonas aeruginosa strain PAO 581, the P. aeruginosa LPS O antigens from serogroups 02 and 06, and the PS/A antigen of Bacteroides fragilis |
| Proposed epitopes | This Mab bound best to PNAG containing N-acetyl groups |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab had partial complement deposition and opsonophagocytic activity. |
| Curator ID | AA + AS |
| Date of Curation | 24-04-2011 |
| References | 16622211 |
|
Bioinformatics Centre, Institute of Microbial Technology, Sec - 39A, Chandigarh, India - 160036 |